retatrutide trial update october 2025 the wonder drug: What's Established, What's Plausible, What's Still a Hypothesis — WellFounded - Founders Health & Concierge Performance Medicine LLY's Retatrutide Nears 2027 Filing

GLP-1 receptors have been identified as expressed on certain tumour cell populations particularly in hormone-sensitive malignancies including endometrial, ovarian, and some breast cancers, as well as meningiomas

Obesity 15 , 939949 (2007)

This case raised questions about whether GLP-1 medications might trigger autoimmune responses in susceptible individuals, adding another layer of complexity to an already nuanced picture

That gap between 10% and 40% is the difference between seeing meaningful results and wondering why the drops are not working

Lillys small-molecule GLP-1 agonist orforglipron (brand Foundayo) also gained FDA approval in April 2026 for weight loss and is expected to launch in 2027, marking a breakthrough as the first non-peptidic GLP-1 pill ( [35] )

Very happy with everything the shipping speed was great and this product seems very high quality